Creso Pharma: Reaches 3 million sale milestone for Anibidiol
- Creso Pharma has now sold over 3 million doses of its anibidiol granule sachets since its launch in 2017
- The granules are a form of complementary feed, designed to reduce stress and improve wellbeing in dogs
- Creso produces cannabis and hemp based products to improve both human and animal health and wellbeing
- The hemp-derived range commercialised in partnership with Vibrac and sold in over 10 European countries
- Sales from the range grew around 700 per cent in 2019
- Creso Pharma says it has another three hemp-derived products slated for launch this year
- Company shares lost 2.63 per cent today to close at 18.5 cents apiece
